Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-targeting CLDN18.2/PD-L1 CAR-T in Advanced Solid Tumors
NCT06084286Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CLDN18.2 CAR-T cells + PD-L1 CAR-T cells in solid tumor (advanced stage), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more, sponsored by Sichuan University. Primary endpoints: Adverse Events at 28 days, Dose-limiting toxicity at 28 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
CLDN18.2 CAR-T cells + PD-L1 CAR-T cells
03
Conditions
solid tumor (advanced stage)gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06084286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084286.